行情

ASND

ASND

Ascendis制药
NASDAQ

实时行情|Nasdaq Last Sale

121.97
+0.17
+0.14%
盘后: 121.97 0 0.00% 16:00 04/08 EDT
开盘
124.76
昨收
121.80
最高
124.76
最低
118.13
成交量
18.17万
成交额
--
52周最高
145.59
52周最低
90.06
市值
58.53亿
市盈率(TTM)
-23.1856
分时
5日
1月
3月
1年
5年

分析师评级

12位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测ASND价格均价为168.14,最高价位199.06,最低价为139.04。

EPS

ASND 新闻

更多
  • 沪指横盘震荡 标普500暂时脱离“技术性熊市”
  • 新浪财经 · 12分钟前
  • 沙特与俄罗斯开会磋商减产 美国敲边鼓旁观
  • 新浪财经综合 · 54分钟前
  • 美国疾控中心:必要产业员工复工 必须戴口罩量体温
  • 新浪财经综合 · 1小时前
  • 趣店跨界做奢侈品电商 百亿补贴引流背后前景难料
  • 投中网 · 1小时前

所属板块

生物技术和医学研究
+3.06%
制药与医学研究
+2.82%

热门股票

代码
价格
涨跌幅

ASND 简况

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. It is also using its TransCon technology platform to develop TransCon Parathyroid Hormone (TransCon PTH) for hypoparathyroidism, a rare endocrine disorder of calcium and phosphate metabolism.
展开

微牛提供Ascendis Pharma A/S(NASDAQ-ASND)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ASND股票新闻,以帮助您做出投资决策。